-$0.17 Earnings Per Share Expected for Aurinia Pharmaceuticals Inc (AUPH) This Quarter

Wall Street brokerages expect that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce ($0.17) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Aurinia Pharmaceuticals’ earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.20). Aurinia Pharmaceuticals posted earnings per share of ($0.04) during the same quarter last year, which would suggest a negative year over year growth rate of 325%. The company is expected to announce its next quarterly earnings results on Thursday, March 21st.

On average, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($0.71) per share for the current year, with EPS estimates ranging from ($0.76) to ($0.62). For the next financial year, analysts anticipate that the company will report earnings of ($0.73) per share, with EPS estimates ranging from ($0.95) to ($0.45). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Aurinia Pharmaceuticals had a negative net margin of 7,280.85% and a negative return on equity of 34.45%. The company had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.07 million.

Several brokerages have recently issued reports on AUPH. BidaskClub upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 target price on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 1st. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, September 26th. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Finally, ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $11.79.

Shares of Aurinia Pharmaceuticals stock opened at $5.65 on Friday. Aurinia Pharmaceuticals has a 12-month low of $4.41 and a 12-month high of $6.69. The firm has a market capitalization of $477.81 million, a PE ratio of -6.14 and a beta of 2.22.

A number of large investors have recently modified their holdings of AUPH. Stanley Laman Group Ltd. acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth $276,000. Creative Planning boosted its stake in Aurinia Pharmaceuticals by 8.2% during the 2nd quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 13,000 shares during the period. Ironwood Investment Management LLC boosted its stake in Aurinia Pharmaceuticals by 18.0% during the 2nd quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock worth $1,231,000 after purchasing an additional 33,279 shares during the period. Cornerstone Wealth Management LLC acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth $2,000,000. Finally, BlackRock Inc. boosted its stake in Aurinia Pharmaceuticals by 45.2% during the 1st quarter. BlackRock Inc. now owns 1,045,121 shares of the biotechnology company’s stock worth $5,424,000 after purchasing an additional 325,408 shares during the period. Hedge funds and other institutional investors own 24.87% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply